Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus
|
|
- Irma Cross
- 7 years ago
- Views:
Transcription
1 Q J Med 2006; 99: doi: /qjmed/hcl116 Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus J. WEST 1, J. BROUSIL 2, A. GAZIS 3, L. JACKSON 2, P. MANSELL 3, A. BENNETT 4 and G.P. AITHAL 2 From the 1 Division of Epidemiology & Public Health, 2 Wolfson Digestive Diseases Centre and 4 Department of Biomedical Sciences, University of Nottingham Medical School, 3 Divisions of Diabetes & Endocrinology and Queen s Medical Centre, Nottingham, UK Received 25 April 2006 and in revised form 3 July 2006 Summary Background: The risk of chronic liver disease is higher in diabetics, and serum alanine transaminase (ALT) is a sensitive predictor of mortality from liver disease. Aim: To estimate the prevalence of elevated ALT in type 1 and type 2 diabetes, and identify possible risk factors. Methods: We identified all patients (n ¼ 2077) attending review between September 2002 and August We excluded those with no ALT measurement (n ¼ 73); those whose alcohol consumption was 414 units/week (women) (n ¼ 276) or 421 units/week (men) (n ¼ 324); and those with a diagnosis of Maturity Onset Diabetes of the Young, secondary diabetes, gestational diabetes or uncertain type of diabetes (n ¼ 51). We calculated the prevalences of elevated ALT in both type 1 and type 2 diabetes patients, and compared the Introduction Diabetes mellitus (DM) is associated with non-alcoholic fatty liver disease (NAFLD) including its severe form, non-alcoholic steatohepatitis (NASH). 1,2 Among patients with diabetes, the risk of chronic liver disease is doubled, independent of alcoholic liver disease or viral hepatitis. 3 Diabetes also increases the risk of primary liver cancers 3 5 and death from liver cirrhosis. 6,7 However, the prevalence of previously undetected liver disease demographic, microvascular risk factors and current drug use between each group using multivariate logistic regression. Results: Of 1353 patients included, 836 (61.9%) had type 2 diabetes. Elevated ALT was found in 9.5% (95%CI %) of patients with type 1 diabetes, and 12.1% (95%CI %) of those with type 2 diabetes. The risk of elevated ALT in patients with type 2 diabetes increased with increasing body mass index (p trend ¼ 0.04), and was lower in those taking insulin (OR 0.38, 95%CI ). Discussion: The prevalence of elevated ALT is 3 4 times higher in patients with either type 1 or type 2 diabetes than in the general population. Further studies investigating the aetiology and mechanisms of this elevation may suggest appropriate early interventions. in a large unselected diabetic population has not been examined. 7 Alanine transaminase (ALT) is a widely available serum marker of liver disease. Even a minor elevation of ALT is a good predictor of mortality from liver disease. 8 In previous reports, including one from our centre, NAFLD was the most common diagnosis, accounting for 64 90% of cases, when detailed investigations were carried out in patients Address correspondence to Dr G.P. Aithal, Consultant Hepatobiliary Physician, D Floor, South Block, Queen s Medical Centre University Hospital, Nottingham NG7 2UH, UK. guru.aithal@qmc.nhs.uk! The Author Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 872 J. West et al. with asymptomatic elevated liver enzymes In a large population-based study analysing data from the Third National Health and Nutrition Examination Survey (NHANES III), ALT elevation was associated with a number of risk factors of NAFLD, such as impaired glucose metabolism, insulin resistance, central obesity, high leptin and triglycerides, even when patients with known diabetes (who are at high risk for NAFLD) were excluded. 12 Hence, raised ALT has been used as a marker of NAFLD in epidemiological studies. 13 In the current study, we have estimated the prevalence of and risk factors for elevated ALT in both Type 1 and Type 2 diabetes. Methods Queen s Medical Centre serves a population of about Of prevalent cases, about 15% of type 2 and 95% of type 1 diabetes attend hospital diabetes services at any one time. From our Diabetic Registry, we identified all those who attended for review between September 2002 and August Data collected prospectively included age, gender, type of diabetes, height, weight, blood pressure, self-reported alcohol intake at the time of registration on the database (and updated during clinical practice), microvascular risk factors and current medications. During the study period, the routine laboratory measurements included: urea and electrolytes; HbA 1c ; lipid profile and liver profile (including ALT, -glutamyl transferase, alkaline phosphatase, bilirubin and albumin). ALT was estimated using Vitros dry-slide analysis (Johnson & Johnson, Ortho Clinical Diagnostics). Hypertension was defined as either current use of anti-hypertensive medication or blood pressure 4140/80 mmhg. Microalbuminuria was defined as either dipstick positive for protein or albumin/ creatinine ratio (in mg/mmol) of 42.5 for women or 43.5 for men. Dyslipidaemia was defined as at least one of: current use of lipid-lowering medication; serum cholesterol 45 mmol/l; LDL 43 mmol/l; triglyceride 42.3 mmol/l; HDL <1 mmol/l. 14 We categorized body mass index (BMI) into standard categories, current age into 10-year age bands, and HbA 1c into quartiles. We defined elevated ALT as 450 IU/l. Statistical analyses We calculated the prevalence and 95%CIs of elevated ALT in both type 1 and type 2 diabetes, and compared the demographic, microvascular risk factors and current drug use between each group. To assess the risk factors for elevated ALT, we used multivariable logistic regression modelling, including all covariates. In the multivariate analyses, we only included those people with no missing values. To examine linear trends, we fitted categorical variables as quantitative variables and assessed goodness-of-fit of the nested models using likelihood ratio tests. All analyses used Stata 7.0/SE. Results We identified 2077 people (of 2999 on the database at the time of the study) who attended for review during the 1-year study period. We excluded those who did not have ALT measured (n ¼ 73), those whose alcohol consumption exceeded 14 units/week for women (n ¼ 276) or 21 units/ week for men (n ¼ 324), and those with a diagnosis of Maturity Onset Diabetes of the Young, secondary diabetes, gestational diabetes or uncertain type of diabetes (n ¼ 51). Of the 1353 patients included, 836 (61.9%) had type 2 diabetes. Elevated ALT was found in 9.5% (95%CI %) of those with type 1 diabetes and 12.1% (95%CI %) of those with type 2 diabetes. Table 1 shows the characteristics of the included subjects by ALT category, and the unadjusted risk estimates for association with each characteristic. There were missing values in only the body mass index and HbA 1c variables. Table 2 shows the multivariable analyses of the risk of elevated ALT from various characteristics. The prevalence of elevated ALT decreased with increasing age in type 2 diabetes (although not statistically significant at the 5% level). In type 2 diabetes, the risk of elevated ALT increased with increasing BMI category (430 vs. 425, OR 2.76, 95%CI , p trend ¼ 0.04) and decreased with current treatment with insulin (OR 0.38, 95%CI ). Discussion The prevalences of elevated ALT in our type 1 (9.5%) and type 2 (12.1%) diabetes patients were both considerably higher than the 2.7% expected in the general population, 8 and higher than 5.6% reported at baseline in clinical trials. 15 This suggests that about 10% of diabetes patients under regular review in secondary care may need further investigation for the causes of raised ALT, and has potential resource implications. However, these prevalences of raised ALT may still be underestimates, for two reasons. Firstly, a single estimation of ALT was used to define abnormality. Fluctuation in the ALT levels
3 ALT elevation in diabetes 873 Table 1 Numbers, proportions and unadjusted ORs for abnormal ALT in patients with type 1 or type 2 diabetes, for various characteristics Diabetes... Type 1 (n ¼ 517) Type 2 (n ¼ 836) ALT... Normal (n ¼ 468) Abnormal (n ¼ 49) OR (95%CI) Normal (n ¼ 735) Abnormal (n ¼ 101) OR (95%CI) Age group (years) (93.6%) 2 (6.5%) 0.49 ( ) 1 (50.0%) 1 (50.0%) 5.89 ( ) (91.8%) 10 (8.2%) 0.63 ( ) 9 (69.2%) 5 (35.7%) 3.27 ( ) (87.6%) 18 (12.4%) 1 53 (85.5%) 9 (14.5%) (88.9%) 12 (11.1%) 0.88 ( ) 100 (81.3%) 23 (18.7%) 1.35 ( ) (98.3%) 1 (1.8%) 0.13 ( ) 206 (85.1%) 36 (14.9%) 1.03 ( ) (87.2%) 5 (12.8%) 1.04 ( ) 242 (92.4%) 20 (7.6%) 0.49 ( ) (93.3%) 1 (6.7%) 0.50 ( ) 124 (94.7%) 7 (5.3%) 0.33 ( ) Gender Female 226 (93.4%) 16 (6.6%) (90.7%) 35 (9.3%) 1 Male 242 (88.0%) 33 (12.0%) 1.93 ( ) 393 (85.6%) 66 (14.4%) 1.64 ( ) BMI (91.8%) 13 (8.2%) 1 85 (95.5%) 4 (4.5%) (91.7%) 15 (8.3%) 1.01 ( ) 189 (89.2%) 23 (10.8%) 2.59 ( ) (94.2%) 6 (5.8%) 0.69 ( ) 347 (87.4%) 50 (12.6%) 3.06 ( ) Missing 58 (79.5%) 15 (20.5%) 114 (82.6%) 24 (17.4%) Microalbuminuria No 268 (92.4%) 22 (7.6%) (89.0%) 41 (12.0%) 1 Yes 200 (88.1%) 27 (11.9%) 1.64 ( ) 435 (88.9%) 60 (12.1%) 1.01 ( ) Hypertension No 213 (91.4%) 20 (8.6%) 1 89 (84.8%) 16 (15.2%) 1 Yes 255 (89.8%) 29 (10.2%) 1.21 ( ) 646 (89.4%) 85 (11.6%) 0.73 ( ) Dyslipidaemia No 181 (93.3%) 13 (6.7%) 1 93 (88.6%) 12 (11.4%) 1 Yes 287 (88.8%) 36 (11.2%) 1.75 ( ) 642 (87.8%) 89 (12.2%) 1.07 ( ) Metformin No 453 (90.8%) 46 (9.2%) (88.5%) 57 (11.5%) 1 Yes 15 (83.3%) 3 (16.7%) 1.97 ( ) 294 (87.0%) 44 (13.0%) 1.16 ( ) Glitazone No 468 (90.5%) 49 (9.5%) 714 (87.9%) 98 (12.1%) 1 Yes 0 (0.0%) 0 (0.0%) 21 (87.5%) 3 (12.5%) 1.04 ( ) Insulin No 0 (0.0%) 0 (0.0%) 242 (81.5%) 55 (18.5%) 1 Yes 468 (90.5%) 49 (9.5%) 493 (92.5%) 46 (8.5%) 0.41 ( ) HbA 1c quartile (87.5%) 12 (12.5%) (88.6%) 26 (11.4%) (92.1%) 10 (7.9%) 0.6 ( ) 171 (87.2%) 25 (12.8%) 1.14 ( ) (93.9%) 8 (6.1%) 0.46 ( ) 164 (86.8%) 20 (10.6%) 1.18 ( ) (91.5%) 11 (8.5%) 0.65 ( ) 169 (89.4%) 20 (10.6%) 0.92 ( ) Missing 25 (75.8%) 8 (24.2%) 29 (85.3%) 5 (14.7%) Reference category. is recognized in patients with chronic liver disease, and a single measurement can underestimate disease burden. 13 Secondly, we defined ALT 450 U/l as abnormal, according to our laboratory range, which was established from 2 SD of ALT estimations in apparently healthy subjects. This concept of establishing normal ranges for ALT based on apparently healthy subjects has been challenged; recent studies have argued that cut-off values identified using normograms of ALT estimations in apparently normal subjects may miss occult chronic liver disease, and underestimate the population at risk of mortality from liver diseases. 9 We acknowledge that our pragmatic approach to defining elevated ALT may have underestimated the prevalence of NAFLD slightly.
4 874 J. West et al. Table 2 Risk of abnormal ALT in patients with type 1or type 2 diabetes, mutually adjusted for all variables (patients with missing values excluded) Diabetes... Type 1 (n ¼ 433) Type 2 (n ¼ 680) Covariate n OR (95%CI) n OR (95%CI) Age group (years) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Gender Female Male ( ) ( ) BMI ( ) ( ) ( ) ( ) Microalbuminuria No Yes ( ) ( ) Dyslipidaemia No Yes ( ) ( ) Hypertensive No Yes ( ) ( ) Metformin No Yes ( ) ( ) Glitazone No Yes ( ) Insulin No Yes ( ) HbA 1c quartile ( ) ( ) ( ) ( ) ( ) ( ) Reference category. As the study included patients attending their hospital review, there is likely to be some selection bias. This may be particularly true of patients with type 2 diabetes, as only 15% of prevalent cases are under hospital review. A variety of factors, including referral pattern, co-morbidity and poor control, can influence the selection of patients for regular hospital review. Although we have controlled for this to some extent by including HbA 1c in our multivariable analysis, findings of the current study may not be true of an unselected population of type 2 diabetes and will require confirmation in population-based studies. It is unlikely that selection bias would have affected the findings in type 1 diabetes as 95% of such patients are under regular hospital review. Although we have not investigated patients with ALT elevation, high alcohol consumption is unlikely to be a major confounder, as we excluded those with moderate or excess alcohol intake. The prevalence of chronic viral hepatitis in our population is likely to be very low (<1 2%), and hence is
5 ALT elevation in diabetes 875 unlikely to explain the high prevalence of abnormal ALT. Therefore, based on previous reports including that from our centre, we have assumed that the majority of these patients have NAFLD Our finding that patients with type 2 diabetes had a higher risk of elevated ALT with increasing body mass index (p trend ¼ 0.04) is consistent with the well-established association of NAFLD with metabolic syndrome, and is supportive of our underlying assumption. The spectrum of NAFLD, including its severe form NASH, has been consistently associated with insulin resistance and hyperinsulinaemia This has raised a concern that treatment with insulin in type 2 diabetes may aggravate liver disease. Consistent with this, in data from de Marco et al., 6 the standardized mortality ratio from cirrhosis in patients with type 2 diabetes was higher in those treated with insulin (OR 6.8 vs. diet alone) than in those on oral hypoglycaemic agents (OR 4.9 vs. diet alone). 6 However, both hyperglycaemia and hyperinsulinaemia can promote fatty infiltration of the liver. Long-standing type 2 diabetes may be associated with relative insulin deficiency, and appropriate insulin treatment would shift the balance against hepatic steatosis. Therefore, our observation that current insulin use in patients with type 2 diabetes is associated with a reduced risk of elevated ALT is reassuring, but requires confirmation in larger groups. Previous reports of raised liver enzymes in patients with type 1 diabetes have been limited to small case series. 19,20 In reports where patients with liver test abnormalities were investigated in detail, marked accumulation of glycogen and steatohepatitis were demonstrated on liver biopsy. 19,20 We did not identify any statistically significant risk factors in type 1 diabetes, although elevated ALT was slightly more common in men, and appeared to show some association with microalbuminuria and dyslipidaemia. Risk factors for elevated liver enzymes in Type 1 diabetes should be investigated further in future studies. In summary, the prevalence of elevated ALT is 3 4 times higher in patients with either type 1 or type 2 diabetes than in the general population. Further studies investigating the aetiology and mechanisms of this elevation may suggest appropriate early interventions. References 1. Marchesini G, Brizi M, Morselli-Labate A, Blanchi G, Bugianesi E, McCullogh A, Forlani G, Melachionda N. Association of non-alcoholic fatty liver disease and insulin resistance. Am J Med 1999; 107: Matteoni C, Younossi Z, Gramlich T, Bopari N, Liu Y, McCullough N. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: Shahib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: De Marco R, Locatelli F, Zoppini G. Cause-specific mortality in type 2 diabetes. Diabetes Care 1999; 22: Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 2005; 22: Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh II. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br Med J 2004; 328: Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986; 21: Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35: Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum aminotransferase activity in the United States. Gastroenterology 2003; 124: Diehl AM, Clark JM. Defining non-alcoholic fatty liver disease: implications for epidemiological studies. Gastroenterology 2003; 124: NICE 2002/055. Type 2 diabetes management of blood pressure and blood lipids, [ 15. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials. Diabetes Care 2002; 25: Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C,
6 876 J. West et al. Weltman M, George J. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: Olsson R, Wesslan C, William-Olsson T, Zettergren L. Elevated aminotransferases and alkaline phosphatases in unstable diabetes mellitus without ketoacidosis or hypoglycaemia. J Clin Gastroenterol 1989; 11: Munns CFJ, McCrossin RB, Thomsett MJ, Batch J. Hepatic glycogenosis: reversible hepatomegaly in type 1 diabetes. J Paediatr Child Health 2000; 36:
NASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center
NASH: It is not JUST a Fatty Liver Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center Stages of Fatty Liver Disorders Fatty Liver 16-35% of Western
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN MEN WITH TYPE 2 DIABETES
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN MEN WITH TYPE 2 DIABETES D. Bakalov 1, M. Boyanov 1, G. Sheinkova 1, L. Vezenkova 1, G. Prodanova 2, V. Christov 1 1 Endocrinology Clinic 2 Sonography unit
More informationNon-alcoholic fatty liver disease: Prognosis and Treatment
Non-alcoholic fatty liver disease: Prognosis and Treatment Zachary Henry, M.D. Assistant Professor UVA Gastroenterology & Hepatology October 28, 2015 Overview Case Presentation Prognosis Effects of fibrosis
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More informationPrimary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care
Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care This advice has been developed to help GPs with shared care of patients with Non- Alcohol
More informationAbnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London
Abnormal Liver Function Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationNon Alcoholic Steato-Hepatitis (NASH)
Non Alcoholic Steato-Hepatitis (NASH) DISCLAIMER NEITHER THE PUBLISHER NOR THE AUTHORS ASSUME ANY LIABILITY FOR ANY INJURY AND OR DAMAGE TO PERSONS OR PROPERTY ARISING FROM THIS WEBSITE AND ITS CONTENT.
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationBURDEN OF LIVER DISEASE IN BRAZIL
BURDEN OF LIVER DISEASE IN BRAZIL Burden of Liver Disease in Europe Blachier et al. J Hepatol 58:593, 2013 Review of 260 epidemiologic studies of the 5 previous years Cirrhosis is responsible for 170.000
More informationApproach to Abnormal Liver Tests
Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School
More informationAlanine aminotransferase (serum, plasma)
Alanine aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Alanine aminotransferase (ALT) 1.2 Alternative names Systematic name L alanine:2 oxoglutarate aminotransferase
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationComparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases
Available online at wwwpelagiaresearchlibrarycom European Journal of Experimental Biology, 2013, 3(2):280-284 ISSN: 2248 9215 CODEN (USA): EJEBAU Comparative Levels of ALT, AST, ALP and GGT in Liver associated
More informationBoehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationThe Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults
The Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults Seán R. Millar, Jennifer M. O Connor, Claire M. Buckley, Patricia M. Kearney, Ivan J. Perry Email:
More informationFreiburg Study. The other 24 subjects had healthy markers closer to what would be considered ideal.
Freiburg Study The Freiburg Study was conducted with 48 healthy human subjects of various ages. None of the test subjects had been diagnosed with any disease prior to the study. None were taking any type
More information2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements
Aspartate aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Aspartate aminotransferase (AST) 1.2 Alternative names Systematic name L aspartate:2 oxoglutarate aminotransferase
More informationBody Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
More informationThe child with abnormal liver function tests
The child with abnormal liver function tests Dr Jane Hartley Consultant Paediatric Hepatologist Birmingham Children s Hospital, UK 1 st Global Congress CIP, Paris 2011 Contents Over view of liver anatomy,
More informationPrevalence of alcohol consumption among Rheumatoid Arthritis patients on Methotrexate and impact on liver function tests
Prevalence of alcohol consumption among Rheumatoid Arthritis patients on Methotrexate and impact on liver function tests Christine Iannaccone, MPH, Michelle Frits, Jing Cui, PhD, Michael Weinblatt MD,
More informationAppendix: Description of the DIETRON model
Appendix: Description of the DIETRON model Much of the description of the DIETRON model that appears in this appendix is taken from an earlier publication outlining the development of the model (Scarborough
More informationBACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationIS VITAMIN E SAFE TO USE?
Vitamin E & Fatty Liver IS VITAMIN E SAFE TO USE? Nonalcoholic Fatty Liver Disease (NAFLD) & Nonalcoholic Steatohepatitis (NASH) Prevalence: 5.7-16.5% 57 5 in US Usually diagnosed in 40-60 y/o s Non-significant
More informationDeterminants of Abnormal Liver Function Tests in Diabetes Patients in Myanmar
International Journal of Diabetes Research 2012, 1(3): 36-41 DOI: 10.5923/j.diabetes.20120103.02 Determinants of Abnormal Liver Function Tests in Diabetes Patients in Myanmar Han Ni 1,*, Htoo Htoo Kyaw
More informationNutrition Therapy in Diabetes Mellitus. Dorothy Debrah Diabetes Specialist Dietitian University Hospital, Llandough. Wales, UK February 2012
Nutrition Therapy in Diabetes Mellitus. Dorothy Debrah Diabetes Specialist Dietitian University Hospital, Llandough. Wales, UK February 2012 University Hospital Llandough DIABETES MELLITUS. Definition:
More informationHepatic steatosis, the accumulation of lipids in. Long-Term Follow-up of Patients With NAFLD and Elevated Liver Enzymes
Long-Term Follow-up of Patients With NAFLD and Elevated Liver Enzymes Mattias Ekstedt, 1 Lennart E. Franzén, 2 Ulrik L. Mathiesen, 3 Lars Thorelius, 4 Marika Holmqvist, 5 Göran Bodemar, 1 and Stergios
More informationObesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000
P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One
More informationArterial inflammation has emerged as central to the
Association Between Elevated Liver Enzymes and C-Reactive Protein Possible Hepatic Contribution to Systemic Inflammation in the Metabolic Syndrome Arthur Kerner, Ophir Avizohar, Ron Sella, Peter Bartha,
More informationNAFLD/NASH: Criteri diagnostici e prognostici
Monotematica AISF Personalizzazione della Cura in Epatologia NAFLD/NASH: Criteri diagnostici e prognostici Pisa 17-19 ottobre 2013 Elisabetta Bugianesi MD, PhD Division of Gastro-Hepatology, University
More informationUsing Liver Enzymes as Screening Tests to Predict Mortality Risk
Copyright E 2008 Journal of Insurance Medicine J Insur Med 2008;40:191 203 LABORATORY TESTING Using Liver Enzymes as Screening Tests to Predict Mortality Risk Michael Fulks, MD; Robert L. Stout, PhD; Vera
More informationEvaluation of abnormal LFT in the asymptomatic patient. Son Do, M.D. Advanced Gastroenterology Vancouver, WA
Evaluation of abnormal LFT in the asymptomatic patient Son Do, M.D. Advanced Gastroenterology Vancouver, WA Definition of chronic, abnormally elevated LFT Elevation of one or more of the following for
More informationLiver Function Tests. Dr Stephen Butler Paediatric Advance Trainee TDHB
Liver Function Tests Dr Stephen Butler Paediatric Advance Trainee TDHB Introduction Case presentation What is the liver? Overview of tests used to measure liver function RJ 10 month old European girl
More informationEducation. Panel. Triglycerides & HDL-C
Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified
More informationAdams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS
Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS Your health is important to us! The test descriptions listed below are for educational purposes only. Laboratory test interpretation
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationNon-alcoholic fatty liver disease in diabetics prevalence and predictive factors in a multiracial hospital clinic population in Malaysia
bs_bs_banner doi:10.1111/jgh.12204 HEPATOLOGY Non-alcoholic fatty liver disease in diabetics prevalence and predictive factors in a multiracial hospital clinic population in Malaysia Wah-Kheong Chan,*
More informationAn Evaluation of the 215GO! Child Obesity Program in the Philadelphia Health Centers. Daniel Morris Walker. Drexel University.
An Evaluation of the 215GO! Child Obesity Program in the Philadelphia Health Centers Daniel Morris Walker Drexel University May 2011 A Community Based Master s Project presented to the faculty of Drexel
More informationUnderstanding Diseases and Treatments with Canadian Real-world Evidence
Understanding Diseases and Treatments with Canadian Real-world Evidence Real-World Evidence for Successful Market Access WHITEPAPER REAL-WORLD EVIDENCE Generating real-world evidence requires the right
More informationAlcoholic Liver Disease and Its Relationship with Metabolic Syndrome
Research and Reviews Alcoholic Liver Disease and Its Relationship with Metabolic Syndrome JMAJ 53(4): 236 242, 2010 Hiromasa ISHII,* 1 Yoshinori HORIE,* 2 Yoshiyuki YAMAGISHI,* 3 Hirotoshi EBINUMA* 3 Abstract
More informationDifferential Diagnosis of NAFLD- A Short Summary:
Differential Diagnosis of NAFLD- A Short Summary: Almost a fifth of our general pediatric population is now classified as overweight in the United States. When such children present with elevated liver
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationHow To Know If You Have Microalbuminuria
3 PREVALENCE AND PREDICTORS OF MICROALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A CROSS-SECTIONAL OBSERVATIONAL STUDY Dr Ashok S Goswami *, Dr Janardan V Bhatt**; Dr Hitesh Patel *** *Associate
More informationLIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
More informationNon-alcoholic fatty liver disease
Journal of Gastroenterology and Hepatology (2002) 17 (Suppl.) S186 S190 QUADRENNIAL REVIEW Non-alcoholic fatty liver disease PAUL ANGULO AND KEITH D LINDOR Division of Gastroenterology and Hepatology,
More informationLiver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationDiagnosis, classification and prevention of diabetes
Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3
More informationDETERMINANTS OF ABNORMAL LIVER FUNCTION TESTS IN DIABETES TYPE 2 PATIENTS IN SUDAN
Journal of Science e ISSN 2277-3290 Print ISSN 2277-3282 Clinical Chemistry www.journalofscience.net DETERMINANTS OF ABNORMAL LIVER FUNCTION TESTS IN DIABETES TYPE 2 PATIENTS IN SUDAN Hind M. Elmahi 1,
More informationMEDICAL NUTRITION THERAPY (MNT) CLINICAL NUTRITION THERAPY Service Time CPT Code
MEDICAL NUTRITION THERAPY (MNT) CLINICAL NUTRITION THERAPY Service Time CPT Code Initial Assessment And Intervention This Code Can Be Used Only Once A Year For First Appointment Medical Nutrition Therapy
More informationNon-alcoholic Fatty Liver Disease, as a Possible Independent Risk Factor for Obliterative Arteriopathy
RESEARCH ARTICLE Acta Medica Marisiensis 2012;58(5):341-345 Non-alcoholic Fatty Liver Disease, as a Possible Independent Risk Factor for Obliterative Arteriopathy Szalman Krisztina Borbála, Puskás A 2
More informationRenal cell carcinoma and body composition:
Renal cell carcinoma and body composition: Results from a case-control control study Ryan P. Theis, MPH Department of Epidemiology and Biostatistics College of Public Health and Health Professions University
More informationMortality Assessment Technology: A New Tool for Life Insurance Underwriting
Mortality Assessment Technology: A New Tool for Life Insurance Underwriting Guizhou Hu, MD, PhD BioSignia, Inc, Durham, North Carolina Abstract The ability to more accurately predict chronic disease morbidity
More informationNonalcoholic fatty liver disease (NAFLD) has
STEATOHEPATITIS/METABOLIC LIVER DISEASE The Natural History of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis or Cirrhosis: An International Collaborative Study Neeraj Bhala, 1,2,3 Paul Angulo,
More informationNorth of Tyne Area Prescribing Committee
North of Tyne Area Prescribing Committee ANTIPSYCHOTICS IN PSYCHOSIS, BIPOLAR DISORDER AND AUGMENTATION THERAPY IN TREATMENT RESISTANT DEPRESSION Information for Primary Care Updated November 2013 This
More informationClinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.
Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant
More informationAlcohol Abuse and Liver Enzymes (AALE): Results of an Intercompany Study of Mortality
Alcohol Abuse and Liver Enzymes (AALE): Results of an Intercompany Study of Mortality From the Mortality and Morbidity Liaison Committee of the Society of Actuaries (SOA), the American Academy of Insurance
More informationPredictors of Non-Alcoholic Fatty Liver Disease in y e Diabetes
Int J Endocrinol Metab 2007; 2: 61-69 Predictors of Non-Alcoholic Fatty Liver Disease in y e Diabetes ORIGINAL ARTICLE Hosseinpanah F, Rambod M, Sadeghi L Obesity Research Center, Research Intitute for
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationLiver, Gallbladder, Exocrine Pancreas KNH 406
Liver, Gallbladder, Exocrine Pancreas KNH 406 2007 Thomson - Wadsworth LIVER Anatomy - functions With disease blood flow becomes obstructed Bile All bile drains into common hepatic duct Liver Bile complex
More informationOMG my LFT s! How to Interpret and Use Them. OMG my LFT s! OMG my LFT s!
How to Interpret and Use Them René Romero, M.D. Clinical Director, Pediatric Hepatology CPG Gastroenterology, Hepatology and Nutrition Emory University School of Medicine Objectives Understand the anatomy
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More informationPresents: Insider tips for the life insurance medical exam. Know what they are testing for--and how to get the best results.
Presents: Insider tips for the life insurance medical exam. Know what they are testing for--and how to get the best results. Copyright 2012 TheLifeInsuranceInsider.com The material Information presented
More informationInsulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review D Shyangdan, 1 C Clar, 2 N Ghouri,
More informationNew Medicare Preventive
New Medicare Preventive Services Screening Tests You Can Perform in the Office Charles B. Root, PhD Medicare is finally getting serious about preventive services. Until now, the limited preventive testing
More informationOpportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease
Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease 80 Liver Disease and Obesity Liver disease biomarkers: Percent of adult population (United States)
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationRenal Disease in Type 2 Diabetes Mellitus
Renal Disease in Type 2 Diabetes Mellitus 6th Collaborative DiGP/HSE/UCC Conference 25 th September 2013 Dr. Eoin O Sullivan Consultant Endocrinologist Bon Secours Hospital Cork Case 69 year old woman
More informationWhat to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
More informationLiver-related morbidity and mortality in nonalcoholic. Long-Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis C
Long-Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis C Jason M. Hui, 1 James G. Kench, 2 Shivakumar Chitturi, 1 Archana Sud, 1 Geoffrey C. Farrell, 1 Karen Byth, 3 Pauline
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #128 (NQF 0421): Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan National Quality Strategy Domain: Community/Population Health 2016 PQRS OPTIONS F INDIVIDUAL MEASURES:
More informationPrevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationEstimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation
Estimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation Mohammad Ebrahim Ghamar Chehreh 1, Mohsen Vahedi 2, Mohammad Amin Pourhoseingholi 3, Sara Ashtari
More informationTHE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points
December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,
More informationDiabetic Nephropathy
Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal
More informationHepatitis C. Laboratory Tests and Hepatitis C
Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what
More informationAbsolute cardiovascular disease risk assessment
Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk
More informationRecommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center
More informationHepatology Guidelines for Primary Care November 2011
Common requests for hepatology opinion/advice 1. Abnormal LFTs (is this fatty liver?) 2. Fatty Liver Disease (is this serious liver disease?) 3. Abnormal liver ultrasound 4. Alcohol related liver disease
More informationLiver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to
Manifesto by the European Liver Patients Association (ELPA) on policy measures against chronic liver disease 2014 to 2019 Why this manifesto? Every five years European voters get the opportunity to have
More informationTwo Cases of Non-Alcoholic Steato-Hepatitis Developing from Simple Fatty Liver
case series Two Cases of Non-Alcoholic Steato-Hepatitis Developing from Simple Fatty Liver Soo Ryang Kim, Taisuke Nakajima, Kenji Ando, Keiji Mita, Katsumi Fukuda Department of Gastroenterology, Kobe Asahi
More informationThe Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke
More information1.5 Function of analyte For albumin, see separate entry. The immunoglobulins are components of the humoral arm of the immune system.
Total protein (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Total protein 1.2 Alternative names None 1.3 NMLC code 1.4 Description of analyte This is a quantitative measurement
More informationScottish Diabetes Survey 2014. Scottish Diabetes Survey Monitoring Group
Scottish Diabetes Survey 2014 Scottish Diabetes Survey Monitoring Group Contents Table of Contents Contents... 2 Foreword... 4 Executive Summary... 6 Prevalence... 8 Undiagnosed diabetes... 21 Duration
More informationVisual Acuity. Hearing. Height and Weight. Blood Pressure MEASURED VALUE
TEST ITEM DESCRIPTION STANDARD LEVEL Standard level varies among different examination methods. Please check with your medical facility about normal level. MEASURED VALUE Visual Acuity You look at rings
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationType 2 Diabetes. Tabinda Dugal GP Day 4/05/16
Type 2 Diabetes Tabinda Dugal GP Day 4/05/16 Diabetes Diabetes.a growing health crisis in Britain 869m per year 10% of NHS budget Projections.. 5 million by 2025 Youngest patient? T2DM Type 2 diabetes
More informationNonalcoholic fatty liver disease is one of the most
Similarities and Differences in Outcomes of Cirrhosis Due to Nonalcoholic Steatohepatitis and Hepatitis C Arun J. Sanyal, 1 Colin Banas, 1 Carol Sargeant, 1 Velimir A. Luketic, 1 Richard K. Sterling, 1
More informationCase 2:10-md-02179-CJB-SS Document 6427-14 Filed 05/03/12 Page 1 of 5 EXHIBIT 12
Case 2:10-md-02179-CJB-SS Document 6427-14 Filed 05/03/12 Page 1 of 5 EXHIBIT 12 Case 2:10-md-02179-CJB-SS Document 6427-14 Filed 05/03/12 Page 2 of 5 Components of the PERIODIC MEDICAL CONSULTATION PROGRAM
More informationSubproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases
Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases M. Trauner, Division of Gastroenterology and Hepatology, Department of Internal Medicine, MUG Co- Investigator: H. Samonigg,
More informationKansas Behavioral Health Risk Bulletin
Kansas Behavioral Health Risk Bulletin Kansas Department of Health and Environment November 7, 1995 Bureau of Chronic Disease and Health Promotion Vol. 1 No. 12 Diabetes Mellitus in Kansas Diabetes mellitus
More information